ReviewFrontiers in immunology2026
Targeting CD47-mediated cancer senescence, a novel strategy for cancer immunotherapy.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A transmembrane protein that is extensively expressed, CD47 has an important role in the senescence of cancer cells. Therapy-induced senescence (TIS) by chemotherapy and radiotherapy restrains tumor proliferation yet drives immune evasion and treatment resistance, where CD47 acts as a core regulatory molecule linking cellular senescence and tumor immune escape. In this mini-review, we summarize the mechanisms governing CD47 upregulation during TIS, ranging from DNA damage response signaling, metabolic reprogramming and epigenetic modulation to post-transcriptional RNA modification. After addressing how CD47 is upregulated in TIS, we summarized the function of CD47 in both the maintaining the senescent statue and preventing senescent escape. Three major pathways are addressed. TSP-1/CD47 axis functions as both senescence maintenance and preventing escape, while, p16/c-MYC/CD47 axis and CD47/QPCT axis are responsible for senescence maintenance. Moreover, we summarize the therapeutic strategies toward CD47 blockade as s senolytic way, pointing out a novel strategy for oncotherapy. Overall, CD47 is a pivotal molecular bridge between TIS and immune tolerance. Future research on the role CD47 of cancer senescence, especially after chemotherapy or radiotherapy, could provide novel insight for oncotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.